ArticleJournal of translational medicine2026
LAG3 as a potential biomarker in breast cancer: integrated tissue and peripheral blood analysis reveals clinical and pathomic insights in triple-negative disease.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a heterogeneous disease. Triple-negative breast cancer (TNBC) is the most aggressive subtype and lacks reliable biomarkers for immunotherapy. This study aimed to evaluate lymphocyte activation gene 3 (LAG3) as a potential translational biomarker in breast cancer, assessing its expression across molecular subtypes and whether its levels in patients’ peripheral blood match those in tumour tissue, thereby enabling non-invasive monitoring.
methodsThe TCGA genomic database was analysed to investigate the association between LAG3 expression and breast cancer subtypes. These findings were then validated in an independent patient cohort of 50 patients using immunohistochemistry and molecular analysis of peripheral blood mononuclear cells (PBMCs). Digital pathology approaches were also employed, incorporating intensity- and texture-based feature extraction from DAB and ODsum channels to evaluate spatial patterns of marker distribution.
resultsA significant association was identified in the TCGA dataset between high LAG3 expression and the TNBC subtype, and this was confirmed in the validation cohort. LAG3 expression was found only in immune cells and was significantly more prevalent in TNBC. PBMC-derived mRNA levels were consistent with tissue expression, supporting systemic concordance. While the DAB-positive area did not significantly differ among subtypes, digital pathology analyses identified increased spatial heterogeneity in TNBC compared with luminal tumors using intensity - and texture - based features derived from DAB and ODsum channels, highlighting the value of computational pathology in TME characterization.
conclusionsLAG3 is emerging as a promising immune-related biomarker with translational relevance in breast cancer. The observed concordance between tissue and peripheral blood samples suggests that liquid biopsies could be used as a non-invasive tool for immune profiling, patient stratification and longitudinal disease monitoring. This could improve the selection of immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.